Strukturne modifikacije psihodelika u cilju razvoja nehalucinogenih analoga sa antidepresivnim potencijalom

Introduction: Conventional antidepressants (SSRIs, SNRIs), although effective in treating classic forms of depression, exhibit limitations regarding slow onset of action and insufficient efficacy in patients suffering from treatment-resistant depression. Classic psychedelics demonstrate rapid and sustained effects by stimulating neuroplasticity via 5-HT2A receptors. However, their application is constrained by pronounced hallucinogenic effects. Aim: To review and systematize current scientific knowledge on the mechanisms of action of classic psychedelics, as well as to analyze structural modification strategies aimed at developing non-hallucinogenic analogs with potential antidepressant activity and an improved safety profile. Materials and Methods: A literature search of scientific databases – PubMed, MEDLINE, and Google Scholar – was conducted for the period from 2016 to 2026 using relevant keywords. Scientific papers investigating psychedelics, neuroplasticity, 5HT-2A receptors, and structural modifications were analyzed. Results: Specific structural modifications yielded analogs with reduced or completely eliminated hallucinogenic potential while preserving the stimulation of neuroplasticity and BDNF expression. Among tryptamines, bulky substitution of psilocin produced the analog AAZ-A-154. In the ergoline class, C2 bromination of LSD generated BOL-148 (2-bromo-LSD). For phenethylamines, modification of 25C-NBOMe (cyano group introduction and hydroxylation) developed the analog 25CN-NBOH. In ibogaine alkaloids, simplification of the polycyclic skeleton and relocation of the methoxy group yielded tabernanthalog (TBG), successfully eliminating hallucinogenic effects and cardiotoxicity. Conclusion: Rational design and structural modification of classic psychedelics enable the successful decoupling of antidepressant efficacy from hallucinogenic effects. Newly synthesized non-hallucinogenic psychoplastogens represent a highly promising class of future therapeutics that could enable safer, simpler, and more widely accessible management of depressive disorders.

Authors

Publication Details

Journal
Medical Sciences
Published
2026-11-18
DOI
https://doi.org/10.63356/stes.med.2026.004
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Strukturne modifikacije psihodelika u cilju razvoja nehalucinogenih analoga sa antidepresivnim potencijalom

Helena Kuzmanović
Medical Sciences
Psychedelics and Drug Studies
article

Strukturne modifikacije psihodelika u cilju razvoja nehalucinogenih analoga sa antidepresivnim potencijalom

Helena Kuzmanović
article en

Abstract

Introduction: Conventional antidepressants (SSRIs, SNRIs), although effective in treating classic forms of depression, exhibit limitations regarding slow onset of action and insufficient efficacy in patients suffering from treatment-resistant depression. Classic psychedelics demonstrate rapid and sustained effects by stimulating neuroplasticity via 5-HT2A receptors. However, their application is constrained by pronounced hallucinogenic effects. Aim: To review and systematize current scientific knowledge on the mechanisms of action of classic psychedelics, as well as to analyze structural modification strategies aimed at developing non-hallucinogenic analogs with potential antidepressant activity and an improved safety profile. Materials and Methods: A literature search of scientific databases – PubMed, MEDLINE, and Google Scholar – was conducted for the period from 2016 to 2026 using relevant keywords. Scientific papers investigating psychedelics, neuroplasticity, 5HT-2A receptors, and structural modifications were analyzed. Results: Specific structural modifications yielded analogs with reduced or completely eliminated hallucinogenic potential while preserving the stimulation of neuroplasticity and BDNF expression. Among tryptamines, bulky substitution of psilocin produced the analog AAZ-A-154. In the ergoline class, C2 bromination of LSD generated BOL-148 (2-bromo-LSD). For phenethylamines, modification of 25C-NBOMe (cyano group introduction and hydroxylation) developed the analog 25CN-NBOH. In ibogaine alkaloids, simplification of the polycyclic skeleton and relocation of the methoxy group yielded tabernanthalog (TBG), successfully eliminating hallucinogenic effects and cardiotoxicity. Conclusion: Rational design and structural modification of classic psychedelics enable the successful decoupling of antidepressant efficacy from hallucinogenic effects. Newly synthesized non-hallucinogenic psychoplastogens represent a highly promising class of future therapeutics that could enable safer, simpler, and more widely accessible management of depressive disorders.

Medical SciencesVol. 19
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon